LTRN Lantern Pharma Inc
Company Analysis
Latest News
🔴 Lantern Pharma is trading 10.26% down in pre-market; no clear company-specific catalyst
Lantern Pharma is trading 10.26% down at $2.10 in pre-market, with no fresh company-specific announcement clearly explaining the decline. - The latest...
🔴 Lantern Pharma falls 5.6% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🟢 Lantern Pharma is trading 12.85% up today in pre-market with XBI up 2.27%
Lantern Pharma is trading 12.85% up at $2.81 amid biotech sentiment, with XBI up 2.27% pre-market amid positive cancer-trial news. - No verified...
🟢 Lantern Pharma is trading 10.43% up in after-hours trading with no verified catalyst
Lantern Pharma is trading 10.43% up at $2.75 in after-hours trading, with no verified company-specific announcement emerging on August 19, 2026. - Latest...
🟢 Lantern Pharma rises 5.2% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🔴 Lantern Pharma is trading 5.7% down in pre-market after Q2 loss miss and funding warning
Lantern Pharma is trading 5.7% down in pre-market at $2.50 as investors continued digesting its August 14 second-quarter earnings release, including a loss...
Lantern Pharma's Cash Clock Is Ticking — Can Promising Trial Data Outrun a Looming Dilution Squeeze?
Shares of Lantern Pharma (LTRN) tumbled 8.7% to $2.40 on August 14 after second-quarter results exposed a widening gap between the company's clinical ambitions...
🔴 Lantern Pharma is trading 8.75% down today after Q2 loss exceeded analyst expectations
Lantern Pharma is trading 8.75% down at $2.40 after its August 14, 2026, second-quarter results showed a $7.1 million net loss, or $0.57 per share, versus...
Lantern Pharma's second quarter operating loss fell 25% as HARMONIC trial data improved
Lantern Pharma reported a second quarter 2026 loss from operations of $3.5 million, reflecting a 25% improvement year-over-year. While net loss widened to $7.1...
Lantern Pharma Inc Q2 2026 Earnings Preview: What Analysts Expect on August 12, 2026
Lantern Pharma is expected to report a Q2 2026 loss of $0.38 per share on $0 revenue, with its current stock price of $2.88 significantly trailing the average...
Lantern Pharma Gets a European Green Light for Its Lead Cancer Drug — But Can a $37 Million Company Afford to Run the Race?
Shares of Lantern Pharma surged 10.3% to $2.90 after Europe's top drug regulator cleared the company to begin a mid-stage human trial of its lead cancer...
🔴 Lantern Pharma is trading 5.7% down today on profit-taking after AI spin-out rally
Lantern Pharma is trading at $2.64 (5.7% down) as investors lock in gains following a multi-day rally tied to the company's AI-related spin-out. • The decline...
🔴 Lantern Pharma is trading 5.7% down today on profit-taking after recent AI spin-out rally
Lantern Pharma is trading at $2.64 (5.7% down) in after-hours trading on apparent profit-taking following a multi-day rally. • The stock is pulling back from...
🟢 Lantern Pharma is trading 7.3% up today on EMA trial clearance and AI spin-out launch
Lantern Pharma is trading 7.3% up today at $2.80 as investors react to the late-July EMA clearance for its LP-184 Phase 1b/2 trial and the launch of its AI...
🟢 Lantern Pharma is trading 5.3% up today on EMA clearance for bladder cancer trial
Lantern Pharma is trading 5.3% up today at $2.77 as investor momentum builds following a major regulatory milestone in Europe. • The European Medicines Agency...
🟢 Lantern Pharma is trading 10.3% up today after EMA clearance for LP-184 bladder cancer trial
Lantern Pharma is trading at $2.90 (10.3% up) following momentum from the European Medicines Agency (EMA) clearing a Phase 1b/2 trial for its lead candidate,...
Lantern Pharma secures EMA clearance for LP-184, targeting recurrent bladder cancer
Lantern Pharma Inc. received clearance from the European Medicines Agency (EMA) to launch a Phase 1b/2 clinical trial for its lead candidate, LP-184. The study...
🟢 Lantern Pharma is trading 9.6% up today amid a broader risk-on rally in tech stocks
Lantern Pharma is trading at $2.70 (+9.56%) today as part of a broader risk-on move in U.S. equities. • The Nasdaq Composite is up 2.45% as technology stocks...
🔴 Lantern Pharma falls 5.1% — Biotech Stocks Decline on Broad Market Weakness
With Biotech (XBI) down 2.2%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🔴 Lantern Pharma is trading 5.2% down today after hitting a new 52-week low of $2.77
Lantern Pharma is trading 5.2% down today at $2.94 after hitting a new 52-week low of $2.77, extending a steep decline from its prior high of $8.27. • Recent...